Each country will have regulatory bodies responsible for implementing all necessary safety guidelines relating to the production of new drugs. One such safety precaution is the collection of site data at the development phase for clinical trials. Clinical trials are required to observe the physiological actions of the new drugs, as well as their effects on the different known drug target groups.
The collection of site data also involves the preparation of adequate data covering subjects such as the study population, the exposed individuals and the clinical setting. One should not forget that the pharmaceutical companies do not just rely on these data for pre-licensing the new drugs, but also for the successful marketing of the drugs in the future. This is why the clinical trials for new drugs are carefully monitored by numerous parties. For details on Adaptive Phase 1 Clinical Studies, visit Richmond Pharmacology phase 1 clinical studies
The submission of this data enables the regulatory bodies to examine the safety, toxicity and effectiveness of the new drugs. Thus, these agencies closely monitor the new drugs before they are released in the market.
These agencies compile the data they receive from the companies, and from the subjects who have been involved in the trial, and they post this information on their websites. One of the best ways of learning how new drugs are tested is by consulting with an agency directly, rather than going through a drug company.